RELEPOST 20 MG/G CUTANEOUS BAR
How to use RELEPOST 20 MG/G CUTANEOUS BAR
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Relepost 20 mg/g Cutaneous Bar
Tripelennamine Hydrochloride
Read the entire package leaflet carefully before starting to use this medication, as it contains important information for you. Follow the administration instructions of the medication contained in this package leaflet exactly or as indicated by your doctor or pharmacist.
Consult a doctor if it worsens or does not improve after 4 days.
|
Contents of the Package Leaflet
- What is Relepost and what is it used for
- What you need to know before using Relepost
- How to use Relepost
- Possible side effects
- Storage of Relepost
- Contents of the pack and further information
1. What is Relepost and what is it used for
It contains tripelennamine hydrochloride as the active ingredient, which is an antihistamine, a medication used on the skin to eliminate or reduce the effects of allergies, thereby reducing symptoms such as itching or pain caused by certain agents.
Relepost is used for the temporary relief of itching, pain, or stinging due to insect bites or contact with jellyfish or nettles, or itching due to mild skin irritations.
2. What you need to know before using Relepost
Do not use Relepost:
- If you are allergic to tripelennamine or related compounds or to any of the other components of this medication (listed in section 6).
- If you have a skin inflammation with fluid secretion and/or small blisters (exudative and/or vesicular dermatitis).
- In children under 2 years of age.
- On large areas of skin and in case of skin inflammation around the affected area.
Warnings and precautions
Consult your doctor or pharmacist before starting to use Relepost.
Do not use on open wounds.
In case of allergy to the active ingredient of this medication or the related substance ethylenediamine, you may also have cross-sensitivity to antihistamine medications, such as aminophylline or hydroxyzine.
Children
This medication should not be used in children under 2 years of age.
In children over 2 years and under 6, the doctor or pharmacist should assess its use, as although absorption is minimal, sedative effects and others may occur.
Other medications and Relepost
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
No interactions with this medication are known.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your pharmacist before using this medication.
Relepost can be used during pregnancy under prescription and during breastfeeding.
No data are available on whether Relepost affects fertility.
Driving and using machines
Relepost has no influence on the ability to drive and use machines.
Relepost contains propylene glycol (E1520).
This medication contains 715 mg of propylene glycol per gram.
Propylene glycol may cause skin irritation.
3. How to use Relepost
Follow the administration instructions of the medication contained in this package leaflet exactly or as indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist.
The recommended dose is:
- Adults and children over 6 years of age:
Relepost is applied to the affected skin area. Repeat if necessary, up to 3 or 4 times a day.
For cutaneous use.
Slide the bar with a gentle massage on the affected area.
Apply only to small-sized conditions (no larger than the size of the palm of the hand) for short-term treatments (maximum 7 days).
Do not use on damaged skin (or on wounds).
Use in children
This medication should not be used in children under 2 years of age.
In children over 2 years and under 6, the doctor or pharmacist should assess its use.
If you use more Relepost than you should
With a cutaneous bar, overdose is not relevant.
In case of systemic intoxication, symptoms may include lethargy, agitation, confusion, tinnitus, blurred vision, dilated pupils, dry mouth, flushing, fever, tremors, insomnia, and hallucinations. Toxic reactions have been reported in a child (agitation, convulsions, ...) in whom it was used on a large area of the body.
In case of overdose or accidental ingestion, go immediately to a medical center, consult your doctor or pharmacist, or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to use Relepost
Do not use a double dose to make up for forgotten doses.
Apply the dose as soon as you remember and the next dose at the usual time.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
4. Possible side effects
Like all medications, this medication can cause side effects, although not everyone experiences them.
The most characteristic adverse reaction that may occur is irritation and mild allergic reactions on contact.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
5. Storage of Relepost
Keep this medication out of the sight and reach of children.
Store in the original packaging, tightly closed. Do not store at a temperature above 25°C.
Do not refrigerate or freeze.
Do not use this medication after the expiration date shown on the box and on the base of the cutaneous bar applicator after CAD. The expiration date is the last day of the month indicated.
Do not use this medication if you notice a color different from white or a soft product consistency.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
6. Contents of the pack and further information
Composition of Relepost
The active ingredient is tripelennamine hydrochloride. Each gram contains 20 mg of tripelennamine hydrochloride (2%).
The other components (excipients) are: propylene glycol (E1520), sodium stearate, and water.
Appearance of the product and contents of the pack
White, oval-shaped, and consistent cutaneous bar.
Each applicator contains 5.7 grams.
Marketing authorization holder and manufacturer
Marketing authorization holder
Perrigo España S.A.
Pza. Xavier Cugat, 2 – Edif. D, Pl. 1ª
08174 Sant Cugat del Vallès (Barcelona), España
Manufacturer
Medgenix Benelux NV
Vliegveld 21
Wevelgem, 8560
Belgium
Date of the last revision of this package leaflet:March 2024
Detailed information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
- Country of registration
- Active substance
- Prescription requiredNo
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to RELEPOST 20 MG/G CUTANEOUS BARDosage form: GEL, 1 mg/gActive substance: dimetindeneManufacturer: Laboratorios Normon S.A.Prescription not requiredDosage form: GEL, 1 mg/gActive substance: dimetindeneManufacturer: Grindeks AsPrescription not requiredDosage form: GEL, 100 mg dimetindene maleateActive substance: dimetindeneManufacturer: Haleon Spain S.A.Prescription not required
Online doctors for RELEPOST 20 MG/G CUTANEOUS BAR
Discuss questions about RELEPOST 20 MG/G CUTANEOUS BAR, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions